Alexis Desieno Sells 25,118 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the sale, the chief financial officer now owns 116,481 shares of the company’s stock, valued at $399,529.83. The trade was a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Alexis Desieno also recently made the following trade(s):

• On Wednesday, October 2nd, Alexis Desieno sold 7,487 shares of Cardlytics stock. The shares were sold at an average price of $3.08, for a total value of $23,059.96.

Cardlytics Stock Performance

Shares of NASDAQ CDLX opened at $3.38 on Monday. Cardlytics, Inc. has a one year low of $2.89 and a one year high of $20.52. The business’s 50-day moving average price is $3.72 and its two-hundred day moving average price is $6.33. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The company has a market capitalization of $171.78 million, a P/E ratio of -0.55 and a beta of 1.61.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. The firm had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm’s revenue was down 15.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) earnings per share. Analysts anticipate that Cardlytics, Inc. will post -1.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CDLX has been the topic of a number of recent research reports. Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Northland Securities downgraded shares of Cardlytics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. Finally, Evercore ISI assumed coverage on shares of Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.92.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd acquired a new position in shares of Cardlytics during the 1st quarter worth about $1,906,000. GSA Capital Partners LLP lifted its holdings in shares of Cardlytics by 1,273.2% during the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after buying an additional 354,474 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock valued at $2,882,000 after acquiring an additional 307,800 shares during the period. Vanguard Group Inc. grew its stake in shares of Cardlytics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after acquiring an additional 57,805 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Cardlytics during the third quarter worth $45,000. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.